J&J Q3 2026 Paradox: EPS $2.59 BEATS Estimates — So Why Is the Stock FALLING?

Johnson & Johnson just delivered a quarter that beat on both revenue and adjusted earnings. The company raised its full-year guidance. Yet the stock fell more than 3% in premarket trading. That contradiction — strong results, negative price reaction — is the entire story, and this video breaks it down. 📊 Q3 2026 earnings highlights: JNJ reported revenue of $25.40 billion, beating the consensus estimate of $25.28 billion and growing 5.9% year-over-year. Adjusted earnings per share came in at $2.59, exceeding the $2.53 consensus by $0.06. However, reported diluted EPS collapsed to $0.09 from $2.12 a year earlier — a 95.8% decline — driven by one-time charges related to the proposed talc litigation settlement, the Firefly Bio acquisition, and the Sail Biomedicines collaboration. Adjusted net earnings still fell 6.8% year-over-year to $6.34 billion. 💊 What’s working: The Innovative Medicine segment — J&J’s pharmaceutical division — grew 7.7% to $16.76 billion. Tremfya sales surged 68.3% to $2.39 billion, offsetting a 54.4% decline in Stelara ($716 million) as generic competition intensified. Darzalex grew 15.4% to $4.24 billion. CEO Joaquin Duato highlighted “accelerating momentum of our focused portfolio” and pointed to OTTAVA, the world’s first table-integrated soft tissue robotic system, as a transformative MedTech innovation. ⚠️ What’s breaking: The MedTech division grew just 2.5% to $8.64 billion — well below expectations. International sales were dragged down by Middle East tensions, European spending cuts, and pricing pressure in China. CFO Joe Wolk noted that regional governments are redirecting budgets toward defense. Abiomed’s Impella heart pumps also remained weak after a UK study raised safety concerns. The stock fell more than 3% in premarket trading on these headwinds. 📈 The guidance upgrade: J&J raised its full-year 2026 adjusted EPS guidance to $11.05–$11.15 from $10.96–$11.11, with a midpoint of $11.10 — a $0.06 increase. Revenue guidance was lifted